Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the SEMA5B gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both SEMA5B-derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors) such as esophageal cancer, NSCLC, RCC and SCLC, and/or the prevention of a metastatic or postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from SEMA5B, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.本文中描述抗癌之胜肽疫苗,特別是關於經分離的抗原決定位胜肽,其源自誘發細胞毒殺性T淋巴球之SEMA5B基因,且因此適合用於癌症免疫治療領域。本發明之胜肽包括SEMA5B衍生之胜肽與其經修飾之形式兩者,於經修飾之形式中,一、二或數個胺基酸被取代、刪除、插入或加入,但仍保留原始序列必要之誘發細胞毒殺性T淋巴球的能力。更提供編碼出此些胜肽的多核苷酸與包括任何上述胜肽或多核苷酸的藥物組合物。並提供以此些胜肽為標的之抗原呈現細胞及經分離之細胞毒殺性T淋巴球,以及誘發此抗原呈現細胞或細胞毒殺性T淋巴球之方法。此外,本發明提供癌症(腫瘤)治療及/或預防治療(prophylaxis)(預防)之方法,例如:食道癌(esophageal cancer)、非小細胞肺癌(NSCLC)、腎細胞癌(RCC)、小細胞肺癌(SCLC),及/或其預防轉移(prevention of a metastatic)或術後復發(postoperative recurrence)之方法,以及誘發細胞毒殺性T淋巴球之方法、使用源自SEMA5B之胜肽誘發抗腫瘤免疫之方法、編碼出此些胜肽的多核苷酸、表現此些胜肽之抗原呈現細胞或本發明之藥物組合物。
